TABLE 1.
Baseline patient characteristics of included myasthenia gravis patients
| Characteristics | Data |
|---|---|
| Patients, n | 90 |
| Females, n (%) | 55 (61.1) |
| Age at baseline a , median years (range) | 53.5 (18–83) |
| Duration of MG at baseline a , median months (range) | 7 (0–300) |
| Follow‐up, median months (range) | 72 (range: 16–223) |
| Therapy at baseline a , n (%) | |
| None | 0 (0.0) |
| Anticholinesterase monotherapy | 10 (11.1) |
| Immunosuppressive drug therapy | 80 (88.9) |
| MGFA classification at baseline a , n (%) | |
| 0 (remission) | 7 (7.8) |
| I | 21 (23.3) |
| IIA | 13 (14.4) |
| IIB | 19 (21.1) |
| IIIA | 10 (11.1) |
| IIIB | 11 (12.2) |
| IVA | 4 (4.4) |
| IVB | 3 (3.3) |
| V | 2 (2.2) |
| Remission of MG after baseline a , n (%), median months (range) | 76 (84.4), 19 (2–139) |
| Thymectomy, n (%) | 49 (54.4) |
| Thymectomy before baseline a , n (%) | 13 (26.5) |
| Thymectomy 0–12 months after baseline, n (%) | 34 (69.4) |
| Thymectomy >12 months after baseline, n (%) | 2 (4.1) |
| Thymoma, n (%) | 17 (18.9) |
| WHO histological type of thymoma, n (%) | |
| A | 0 (0.0) |
| AB | 4 (23.5) |
| B1 | 3 (17.7) |
| B2 | 5 (29.4) |
| B3 | 4 (23.5) |
| C | 0 (0.0) |
| Unknown | 1 (5.9) |
| Staging of thymoma, n (%) | |
| Early stage thymomas b | 12 (70.6) |
| Advanced stage thymomas c | 2 (11.8) |
| Unknown | 3 (17.6) |
Abbreviations: MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; WHO, World Health Organization.
a
At baseline: first analyses of anti‐acetylcholine receptor antibody serum levels in the Maastricht University Medical Center.
b
Early‐stage thymomas: Masaoka‐Koga stages I and II/TNM < T3N0M0.
c
Advanced‐stage thymomas: Masaoka‐Koga stages III and IV/TNM ≥ T3N0M0.